Physician profile
Kristen Eusebe
NPI 1699550582
$4,587.08
in general payments reported to CMS, 2019-2025
51 companies · $2,200 in 2025
The $2,200 reported for 2025 was more than what 95% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $249 · 2024: $2,138 · 2025: $2,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,587.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $514.38 | 2023-2025 | Enhertu, Imfinzi, Lynparza |
| Janssen Biotech, INC. | $362.90 | 2024-2025 | Tecvayli, Darzalex, Rybrevant |
| Novartis Pharmaceuticals Corporation | $318.78 | 2024-2025 | |
| Astellas Pharma US INC | $275.62 | 2024-2025 | Xospata, Vyloy, Xtandi |
| Merck Sharp & Dohme LLC | $227.13 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $220.64 | 2024-2025 | Fruzaqla, Ninlaro, Iclusig |
| Regeneron Healthcare Solutions, INC. | $210.77 | 2023-2025 | Libtayo, Lynozyfic |
| Pfizer INC. | $184.99 | 2024-2025 | |
| Tempus Ai, INC | $165.38 | 2025 | Xt Cdx |
| Eisai INC. | $150.33 | 2024-2025 | |
| Incyte Corporation | $130.25 | 2024-2025 | Jakafi, Monjuvi |
| Adc Therapeutics America, INC. | $129.14 | 2023-2025 | |
| Genzyme Corporation | $125.55 | 2024-2025 | |
| Servier Pharmaceuticals LLC | $112.12 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $99.07 | 2024-2025 |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $92.99 | 2024-2025 | |
| Daiichi Sankyo INC. | $91.94 | 2024-2025 | Enhertu, Datroway, Vanflyta |
| Karyopharm Therapeutics INC. | $90.04 | 2024-2025 | Xpovio |
| Jazz Pharmaceuticals INC. | $88.19 | 2024-2025 | |
| Sobi, INC | $86.36 | 2024-2025 | |
| Genentech USA, INC. | $56.96 | 2024 | Tecentriq, Tecentriq Hybreza, Alecensa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.94 | 2023-2025 | Gilotrif |
| Stemline Therapeutics INC. | $51.90 | 2024-2025 | Orserdu |
| Pharmaessentia USA Corporation | $46.26 | 2024-2025 | Besremi |
| Blueprint Medicines Corporation | $45.33 | 2024 | Ayvakit |
| Deciphera Pharmaceuticals INC. | $40.12 | 2024 | Qinlock |
| E.R. Squibb & Sons, L.L.C. | $38.91 | 2025 | Opdivo |
| Lilly USA, LLC | $37.98 | 2024-2025 | Verzenio, Retevmo, Jaypirca |
| Alexion Pharmaceuticals, INC. | $36.84 | 2024 | Ultomiris |
| Glaxosmithkline, LLC. | $36.62 | 2024-2025 | Jemperli, Zejula |
| Caris Mpi, INC. | $32.84 | 2025 | Mi Cancer Seek |
| Dendreon Pharmaceuticals LLC | $31.54 | 2025 | Provenge |
| Aveo Pharmaceuticals, INC. | $30.09 | 2025 | |
| Accord Healthcare, INC. | $27.13 | 2025 | |
| Puma Biotechnology, INC. | $27.06 | 2024-2025 | |
| Emd Serono, INC. | $25.48 | 2024 | |
| Syndax Pharmaceuticals, INC. | $25.41 | 2025 | |
| Legend Biotech USA INC. | $23.44 | 2025 | Carvykti |
| Genmab U.S., INC. | $23.14 | 2024 | Epkinly |
| Mirati Therapeutics, INC. | $23.03 | 2024 | Krazati |
| Geron Corporation | $22.40 | 2025 | Rytelo |
| Azurity Pharmaceuticals, INC. | $22.10 | 2025 | Danziten |
| Rigel Pharmaceuticals, INC. | $21.69 | 2024 | Tavalisse, Rezlidhia |
| Exelixis INC. | $20.63 | 2025 | Cabometyx |
| Taiho Oncology, INC. | $20.30 | 2025 | |
| Morphosys, US INC. | $18.15 | 2023 | Monjuvi |
| Shield Therapeutics INC | $16.76 | 2024 | |
| Acrotech Biopharma INC. | $14.51 | 2024 | Beleodaq |
| Tolmar, INC. | $13.66 | 2025 | Rubraca, Eligard |
| Pharmaand Gmbh | $13.66 | 2025 | Rubraca |
| Iovance Biotherapeutics, INC. | $10.63 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Eusebe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.